Sex-Stratified Multi-Omics Identifies Sexually Dimorphic Molecular Targets in Parkinson’s Disease

Abstract

Parkinson’s disease (PD) exhibits well-established sex differences in prevalence and clinical phenotypes, yet the underlying molecular mechanisms remain largely elusive. Here, we conducted a comprehensive sex-stratified multi-omic integration to identify sex-specific causal proteins and biological pathways in PD.

We performed gene-based association analysis, transcriptome-wide association studies (TWAS), and proteome-wide Mendelian randomization (PWMR) with colocalization analysis using GWAS summary statistics from the International PD Genetics Consortium (IPDGC; 12,054 male cases/11,999 controls; 7,384 female cases/12,389 controls) for sex-stratified analyses and Global Parkinson’s Genetics Program (GP2; 34,933 cases/31,009 controls) for sex-combined analyses. Prioritized candidates were further evaluated through MR with brain expression quantitative trait loci (eQTLs) from MetaBrain and differential protein abundance analysis using the Global Neurodegeneration Proteomics Consortium (GNPC; 704 PD cases/5,629 controls in plasma; 78 cases/1,411 controls in cerebrospinal fluid). Additionally, pathway enrichment analysis was performed for prioritized molecules.

Integration across three analytical layers prioritized 102 molecular candidates across 31 unique loci, significant from multiple analyses. Of these, eleven genes reached significance across all three layers, including SNCA, MAPT, and CTSB significant in both sexes; CD160, GPNMB, and LRRC37A2 as male-predominant; STX4 and PRSS53 as female-predominant; and BST1, SCARB2, and LGALS3 significant only in sex-combined analysis. In males, CD160 emerged as a novel candidate with convergent evidence across all three analyses and colocalization, while L3MBTL2 was identified as a novel risk gene from gene-based association and TWAS analyses. In females, STX4 and PRSS53 at the 16p11.2 locus showed female-predominant associations. Pathway enrichment analysis revealed innate immune and SUMOylation pathways in males, with CD160 and L3MBTL2 as key contributors respectively, contrasting with WDR5-mediated chromatin remodeling in females. Brain eQTL-based MR confirmed significant associations for 69 of 86 testable candidates (80.2%) in at least one tissue. Protein abundance analysis confirmed sex-specific patterns, and several candidates showed discordant directions between genetically predicted causal effects and observed protein abundance — including male-specific plasma elevation of CD160 and female-specific patterns for STX4 — underscoring the distinction between causal risk mechanisms and disease-state molecular changes.

These findings demonstrate that PD is a molecularly heterogeneous disorder with sexually dimorphic pathogenic drivers. While shared axes such as lysosomal dysfunction and vesicle trafficking disruption exist, the divergence into male-specific immune dysregulation and female-specific chromatin remodeling suggests that the primary triggers of neurodegeneration differ by sex. Our results underscore the necessity of sex-stratified approaches in biomarker discovery and the development of precision therapeutic strategies for PD.